Cogent Biosciences (COGT) Expected to Announce Earnings on Tuesday

Cogent Biosciences (NASDAQ:COGT) will likely be releasing its Q1 2026 results before the market opens on Tuesday, May 5th. Analysts expect Cogent Biosciences to post earnings of ($0.53) per share for the quarter. Interested persons may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 12:30 PM ET.

Cogent Biosciences (NASDAQ:COGT) last released its quarterly earnings data on Tuesday, February 17th. The technology company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). On average, analysts expect Cogent Biosciences to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Cogent Biosciences Stock Performance

COGT opened at $36.63 on Monday. Cogent Biosciences has a one year low of $4.55 and a one year high of $43.73. The company has a market cap of $6.26 billion, a P/E ratio of -16.96 and a beta of 0.37. The company has a debt-to-equity ratio of 0.41, a quick ratio of 14.23 and a current ratio of 14.23. The business’s 50-day simple moving average is $36.47 and its 200-day simple moving average is $34.40.

Wall Street Analyst Weigh In

A number of research firms have recently commented on COGT. Wedbush reiterated an “outperform” rating and issued a $55.00 price objective on shares of Cogent Biosciences in a report on Tuesday, March 17th. Robert W. Baird set a $35.00 price objective on Cogent Biosciences in a report on Thursday, February 19th. HC Wainwright increased their price objective on Cogent Biosciences to $52.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. Jefferies Financial Group began coverage on Cogent Biosciences in a report on Monday, March 16th. They issued a “buy” rating and a $55.00 price objective on the stock. Finally, Wall Street Zen downgraded Cogent Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, January 31st. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $43.45.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Osaic Holdings Inc. grew its stake in Cogent Biosciences by 41.4% during the 2nd quarter. Osaic Holdings Inc. now owns 4,550 shares of the technology company’s stock worth $33,000 after buying an additional 1,333 shares during the last quarter. Strs Ohio purchased a new position in Cogent Biosciences during the 1st quarter worth approximately $36,000. Global Retirement Partners LLC purchased a new position in Cogent Biosciences during the 4th quarter worth approximately $37,000. PNC Financial Services Group Inc. grew its stake in Cogent Biosciences by 414.5% during the 4th quarter. PNC Financial Services Group Inc. now owns 1,281 shares of the technology company’s stock worth $46,000 after buying an additional 1,032 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC grew its stake in Cogent Biosciences by 16.1% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 2,159 shares of the technology company’s stock worth $77,000 after buying an additional 300 shares during the last quarter.

About Cogent Biosciences

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.